Categories: Business

Alibaba Stock Deserves a Better Price Target, but It’s Still a ‘Sell,’ Says J.P. Morgan

[ad_1]

Tuesday was a bad news, good news kind of a day for investors in Chinese large-cap tech titan Alibaba Group (BABA).

Bad news first: JPMorgan analyst Alex Yao reduced his bank’s forecast for Alibaba’s revenue in calendar years 2022 and 2023, shaving off 2% this year, and 5% next. Yao also cut his “non-GAAP EPS estimates” for Alibaba by 9% in 2022, and by a whopping 22% in 2023, reflecting “more cautious assumptions of cost optimization efforts and the de-leveraging of business scale.” GAAP earnings got revised lower by an even harsher 15% (in 2022) and 31% (in 2023).

As the analyst explained, Alibaba’s near-term results face “downside risks to… consensus expectation for March quarter and June quarter results” in 2022, as “the impact from the COVID-19 resurgence negatively affects the domestic ecommerce operation. The resurgence of COVID-19 cases forced Shanghai to go into a full lockdown on 1 April,” and Shanghai alone accounts for about 4% of Alibaba’s retail sales in China. Shenzhen was also locked down for “a couple of weeks in March,” as were “several other provinces/cities.”

Combined, Yao expects these lockdowns will subtract several percentage points of sales growth from Alibaba’s March and April results. As a result, JPMorgan is now expecting that sales will not grow, but rather shrink year over year in the first half of calendar year 2022, falling 4% in the March quarter and 2% in the June quarter. And looking out a bit further, the analyst forecasts no more than 1% and 4% sales growth in the September and December quarters, respectively.

Nor will Alibaba’s other, non-e-commerce business lines fare any better. To the contrary, Yao sees “downside risks for most of Alibaba’s business segments’ growth outlook in the coming two quarters,” with lockdowns disrupting “local consumer services,” the Russia-Ukraine war messing up logistics and depressing international business, and finally cloud computing growth suffering from weak demand in the year’s first half. Growth will be good enough to keep revenues still rising — 18% company-wide in 2022, and 11% in 2023 — but earnings are expected to decline in both years.

So that’s the bad news. Now the good news:

Yao raised his price target on Alibaba stock from $65 a share to $75 a share, despite lowering expectations for both sales and earnings for the year. Citing “improving market sentiment after China’s Vice Premier Liu He gave a pro economy growth speech in mid-March,” and also reduced (U.S.) delisting risk in light of “the newly announced consultation paper on overseas listing regulations by China SEC,” Yao sees investors as likely willing to pay as much as 11 times even reduced 2022 earnings to own a piece of Alibaba today, versus a previous prediction of 7x his former estimate of what Alibaba might earn.

However, even if Yao is right, and Alibaba is worth $75 instead of just $65 a share, Alibaba stock is still overpriced by ~28%. Accordingly, Yao is sticking with his Underweight (i.e. Sell) rating on Alibaba stock. (To watch Yao’s track record, click here)

Yao, however, is the only bear in the picture right now, with the stock displaying a Strong Buy consensus rating. The 12-month average price target stands at $176.03, marking ~70% upside potential from current levels. (See BABA stock forecast on TipRanks)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

[ad_2]
Source link
Admin

Recent Posts

Super Slot Games Review

Super slots provide the pinnacle of casino gaming with their interactive bonus rounds, captivating graphics,…

4 months ago

The Evolution and Impact of  Nanomedicine

Introduction to Nanomedicine Nanomedicine, a subfield of nanotechnology, involves the application of nanoscale materials and…

4 months ago

Chumba Online Casino Review

Chumba Casino provides an extraordinary online gaming experience. Its sweepstakes model allows players to win…

5 months ago

How to Find the Best Online Casinos to Play For Free

Online casinos provide quick, simple, and highly convenient gambling experiences for their players. Offering a…

5 months ago

How to Achieve a Flawless Complexion with the Right Products

Achieving a flawless complexion is a common skincare goal. With the right face care products, you can enhance…

5 months ago

Creating Ideal Matches: The Mutual Selection of Clients and Businesses

Shared values and goals, transparency, understanding each other's needs, communication, and respecting boundaries are vital…

5 months ago